RBC Capital analyst Ben Hendrix lowered the firm’s price target on NeueHealth (NEUE) to $7 from $8 and keeps a Sector Perform rating on the shares. The company reported solid Q3 results ahead of expectations and the management maintained guidance, though the firm is reducing its price target as it rolls its valuation out to 2025, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEUE: